David A. Siegel Alkermes Plc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Alkermes Plc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 679,700 shares of ALKS stock, worth $16.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

679,700

Previous 1,083,600 37.27%

Holding current value

$16.4 Million

Previous $30.1 Million 38.79%

% of portfolio

0.04%

Previous 0.07%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $10.7 Million - $13.2 Million	-403,900 Reduced 37.27%	679,700 $18.4 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $11.2 Million - $13.7 Million	-477,900 Reduced 30.61%	1,083,600 $30.1 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $3.82 Million - $4.49 Million	140,500 Added 9.89%	1,561,500 $43.7 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $3.16 Million - $3.75 Million	111,400 Added 8.51%	1,421,000 $44.5 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $4.66 Million - $5.34 Million	-184,100 Reduced 12.33%	1,309,600 $36.9 Million

Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $8.21 Million - $9.81 Million	374,000 Added 33.4%	1,493,700 $39 Million
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $1.71 Million - $2.47 Million	-77,600 Reduced 6.48%	1,119,700 $25 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $11.7 Million - $13.6 Million	443,900 Added 58.92%	1,197,300 $35.7 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $3.64 Million - $4.41 Million	157,700 Added 26.47%	753,400 $19.8 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $6.13 Million - $9.16 Million	-285,600 Reduced 32.41%	595,700 $13.9 Million
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $7.42 Million - $10.2 Million	317,300 Added 56.26%	881,300 $27.2 Million
Q2 2021 Aug 16, 2021	BUY	$18.78 - $25.15 $7.66 Million - $10.3 Million	408,000 Added 261.54%	564,000 $13.8 Million
Q1 2021 May 17, 2021	SELL	$18.21 - $23.2 $9.37 Million - $11.9 Million	-514,381 Reduced 76.73%	156,000 $2.91 Million
Q4 2020 Feb 16, 2021	SELL	$15.39 - $22.1 $3.5 Million - $5.02 Million	-227,300 Reduced 25.32%	670,381 $13.4 Million
Q3 2020 Nov 16, 2020	SELL	$16.16 - $20.66 $6.08 Million - $7.78 Million	-376,500 Reduced 29.55%	897,681 $14.9 Million
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $1.49 Million - $2.17 Million	-111,900 Reduced 8.07%	1,274,181 $24.7 Million
Q1 2020 May 15, 2020	SELL	$13.06 - $21.24 $531,542 - $864,467	-40,700 Reduced 2.85%	1,386,081 $20 Million
Q4 2019 Feb 14, 2020	BUY	$17.29 - $21.74 $6.33 Million - $7.96 Million	366,000 Added 34.5%	1,426,781 $29.1 Million
Q3 2019 Nov 14, 2019	BUY	$19.51 - $24.28 $68,285 - $84,980	3,500 Added 0.33%	1,060,781 $20.7 Million
Q2 2019 Aug 14, 2019	BUY	$21.47 - $37.33 $12.1 Million - $21 Million	563,100 Added 113.95%	1,057,281 $23.8 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $10.1 Million - $13 Million	357,300 Added 261.03%	494,181 $18 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $3.22 Million - $5.14 Million	115,265 Added 533.24%	136,881 $4.04 Million
Q3 2018 Nov 14, 2018	SELL	$38.6 - $46.12 $1.7 Million - $2.03 Million	-43,919 Reduced 67.02%	21,616 $917,000
Q2 2018 Aug 14, 2018	SELL	$40.56 - $51.36 $5.64 Million - $7.14 Million	-139,081 Reduced 67.97%	65,535 $2.7 Million
Q1 2018 May 15, 2018	SELL	$53.61 - $67.26 $6.56 Million - $8.23 Million	-122,300 Reduced 37.41%	204,616 $11.9 Million
Q4 2017 Feb 14, 2018	BUY	$47.69 - $55.39 $7.21 Million - $8.38 Million	151,281 Added 86.13%	326,916 $17.9 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $8.63 Million - $9.56 Million	175,635	175,635 $8.93 Million

Others Institutions Holding ALKS

# of Institutions

357

Shares Held

180M

Call Options Held

522K

Put Options Held

463K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $3.96B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account